Vondracek Sheryl F, Hansen Laura B, McDermott Michael T
Department of Clinical Pharmacy, School of Pharmacy, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA.
Pharmacotherapy. 2009 Mar;29(3):305-17. doi: 10.1592/phco.29.3.305.
Although clinically significant bone loss and fractures in healthy premenopausal women are rare, more women are seeking evaluation for osteoporosis from their health care providers. As pharmacists are in an ideal position to influence the management of premenopausal women with osteoporosis, it is important that pharmacists understand the available data on bone loss, fractures, and risk factors and secondary causes for osteoporosis, as well as when to recommend testing and treatment in premenopausal women. Limited data are available; therefore, we conducted a MEDLINE search of the literature from January 1993-August 2008. Studies evaluating bone loss, fractures, and fracture risk in healthy premenopausal women were targeted and summarized; most recommendations are based on expert opinion. A small but statistically significant loss in bone mineral density of 0.25-1%/year by dual-energy x-ray absorptiometry is seen healthy premenopausal women; the clinical significance of this is unknown. Whereas absolute fracture risk is low, premenopausal fractures appear to increase postmenopausal fracture risk by 1.5-3-fold. Risk factors for low bone density appear to be similar between pre- and postmenopausal women. Bone density screening in healthy premenopausal women is not recommended, but bone mineral density testing is advisable for those who have conditions or who receive drug therapy that may cause secondary bone loss. Lifestyle modification emphasizing bone-healthy habits such as adequate calcium and vitamin D nutrition, regular exercise, limitation of caffeine and alcohol consumption, and avoidance of tobacco are essential to the management of osteoporosis risk. The efficacy and safety of osteoporosis drugs have not been adequately demonstrated in premenopausal women. Therefore, pharmacologic interventions cannot be recommended in young women with low bone mass but may be considered in those having a more significant fracture risk, such as those with a previous low-trauma fracture or an identified secondary cause for bone loss.
尽管健康的绝经前女性临床上显著的骨质流失和骨折很少见,但越来越多的女性正寻求医疗服务提供者对其骨质疏松症进行评估。由于药剂师处于影响绝经前骨质疏松症女性管理的理想位置,药剂师了解有关骨质流失、骨折、骨质疏松症的风险因素和继发原因的现有数据,以及何时建议对绝经前女性进行检测和治疗非常重要。现有数据有限;因此,我们对1993年1月至2008年8月的文献进行了MEDLINE检索。针对并总结了评估健康绝经前女性骨质流失、骨折和骨折风险的研究;大多数建议基于专家意见。通过双能X线吸收法,健康绝经前女性每年骨矿物质密度有0.25%至1%的轻微但具有统计学意义的下降;其临床意义尚不清楚。虽然绝对骨折风险较低,但绝经前骨折似乎会使绝经后骨折风险增加1.5至3倍。绝经前和绝经后女性低骨密度的风险因素似乎相似。不建议对健康的绝经前女性进行骨密度筛查,但对于有可能导致继发性骨质流失的疾病或接受药物治疗的女性,建议进行骨矿物质密度检测。强调有益骨骼健康的生活方式改变,如充足的钙和维生素D营养、定期锻炼、限制咖啡因和酒精摄入以及戒烟,对于骨质疏松症风险的管理至关重要。骨质疏松症药物在绝经前女性中的疗效和安全性尚未得到充分证实。因此,对于骨量低的年轻女性,不建议进行药物干预,但对于骨折风险较高的女性,如曾有低创伤骨折或已确定有骨质流失继发原因的女性,可考虑进行药物干预。